Phase I Clinical Trial of Recombinant Meningococcal Group B Vaccine (E. Coli) in a Population Aged 3 Months-50 Years Old

Conditions: Healthy Volunteers Interventions: Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose); Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose); Biological: Placebo control Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials